三連板聯創股份(300343.SZ):子公司生產次氯酸鈉水溶液 用於各類公共場所消毒殺菌
格隆匯2月7日丨聯創股份(300343.SZ)公佈,公司股票連續三個交易日漲停。
公司子公司華安新材的產品中有次氯酸鈉水溶液(84消毒液母液,加一定比例的水即可配成消毒液),該產品用於各類公共場所的消毒殺菌。新型冠狀病毒感染的肺炎疫情爆發以來,公司已累計向湖北疫區及山東淄博市捐贈50餘噸次氯酸鈉水溶液,用户可配製約5000噸消毒液用於公共場所、街道、社區消毒。前述事項相關媒體及投資者均進行了關注。除上述説明事項,公司未發現需要澄清或迴應的媒體報道或市場傳聞;公司未發現其他可能對公司股票交易價格產生重大影響的事件。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.